Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. Oxurion
Thumbnail
November 29, 2019

Upcoming events – Kalvista aims for acuity and a me-too from Sanofi approaches

As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.

Thumbnail
August 20, 2019

Where now for Oxurion?

The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.

Article image
Vantage logo
July 19, 2019

Upcoming events – catalysts approach for Catalyst and Oxurion

Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.

Article image
Vantage logo
July 02, 2019

Bicycle continues skidding despite Oxurion’s endorsement

Vantage logo
October 11, 2017

Kalvista leads the kallikrein eye disease pipeline

Vantage logo
September 22, 2017

Snippet roundup: Teva and Thrombogenics get some short-term relief

Vantage logo
December 02, 2016

Snippet roundup: Deals for Boston and Astra, data for Novo and an approval for Biosurfit

Vantage logo
November 09, 2016

No way to bury Arrowhead and Bioinvent’s bad news

Vantage logo
April 14, 2015

On to the curious for Thrombogenics

Vantage logo
October 29, 2014

Poor industry scorecard drives desmoteplase rescue plan

Vantage logo
October 06, 2014

Acquisitions help define performance of mid and small cap stocks

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.